logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10548894 B1

PDFFull Text
Date of Patent:
Feb. 04, 2020

Filed:

Jan. 19, 2018

Combination therapy

Applicant:

Array Biopharma Inc., Boulder, CO (US);

Inventors:

Giordano Caponigro, Cambridge, MA (US);

Darrin Stuart, Emeryville, CA (US);

Laure De Parseval, Basel, CH;

Assignee:

Array BioPharma Inc., Boulder, CO (US);

Attorney:
Primary Examiner:

Shirley V Gembeh

Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01);
Abstract

Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

Find Patent Forward Citations

Loading…